As of June 17, 2025, Idera Pharmaceuticals Inc (IDRA) reports a ROE (Return on Equity) of 333.04%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Idera Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Idera Pharmaceuticals Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | 333.04% |
| 2020-12-31 | 123.53% |
| 2019-12-31 | 504.64% |
| 2018-12-31 | -93.56% |
| 2017-12-31 | -61.26% |
This slight upward trend highlights how Idera Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Idera Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Idera Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Idera Pharmaceuticals Inc (IDRA) | 333.04% |
| Vaccinex Inc (VCNX) | 748.95% |
| Yield10 Bioscience Inc (YTEN) | 582.16% |
| Navidea Biopharmaceuticals Inc (NAVB) | 179.86% |
| StageZero Life Sciences Ltd (SZLS.TO) | 152.27% |
| Abbvie Inc (ABBV) | 128.66% |
Compared to its competitors, Idera Pharmaceuticals Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.